DOI QR코드

DOI QR Code

Soluble Prokaryotic Expression and Purification of Bioactive Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

  • Do, Bich Hang (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Nguyen, Minh Tan (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Song, Jung-A (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Park, Sangsu (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Yoo, Jiwon (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jang, Jaepyeong (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lee, Sunju (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • So, Seoungjun (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Yoon, Yejin (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kim, Inki (Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Lee, Kyungjin (Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jang, Yeon Jin (Department of Physiology, Cell Dysfunction Research Center, University of Ulsan College of Medicine) ;
  • Choe, Han (Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center)
  • Received : 2017.05.25
  • Accepted : 2017.09.25
  • Published : 2017.12.28

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered as an antitumor agent owing to its ability to induce apoptosis of cancer cells without imparting toxicity toward most normal cells. TRAIL is produced in poor yield because of its insoluble expression in the cytoplasm of E. coli. In this study, we achieved soluble expression of TRAIL by fusing maltose-binding protein (MBP), b'a' domain of protein disulfide isomerase (PDIb'a'), or protein disulfide isomerase at the N-terminus of TRAIL. The TRAIL was purified using subsequent immobilized metal affinity chromatography and amylose-binding chromatography, with the tag removal using tobacco etch virus protease. Approximately 4.5 mg of pure TRAIL was produced from 125 ml flask culture with a purification yield of 71.6%. The endotoxin level of the final product was $0.4EU/{\mu}g$, as measured by the Limulus amebocyte lysate endotoxin assay. The purified TRAIL was validated and shown to cause apoptosis of HeLa cells with an $EC_{50}$ and Hill coefficient of $0.6{{\pm}}0.03nM$ and $2.41{\pm}0.15$, respectively. The high level of apoptosis in HeLa cells following administration of purified TRAIL indicates the significance and novelty of this method for producing high-grade and high-yield TRAIL.

Keywords

References

  1. Wang S, El-Deiry WS. 2003. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633. https://doi.org/10.1038/sj.onc.1207232
  2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271: 12687-12690. https://doi.org/10.1074/jbc.271.22.12687
  3. Kimberley FC, Screaton GR. 2004. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 14: 359-372. https://doi.org/10.1038/sj.cr.7290236
  4. Malhi H, Gores GJ. 2006. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25: 7333-7335. https://doi.org/10.1038/sj.onc.1209765
  5. Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, et al. 2000. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39: 633-640. https://doi.org/10.1021/bi992242l
  6. Bodmer JL, Meier P , Tschopp J, Schneider P. 2000. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J. Biol. Chem. 275: 20632-20637. https://doi.org/10.1074/jbc.M909721199
  7. Szliszka E, Mazur B, Zydowicz G, Czuba ZP, Krol W. 2009. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Folia Histochem. Cytobiol. 47: 579-585.
  8. LeBlanc HN, Ashkenazi A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10: 66-75. https://doi.org/10.1038/sj.cdd.4401187
  9. Holen I, Croucher PI, Hamdy FC, Eaton CL. 2002. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62: 1619-1623.
  10. Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, et al. 2003. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 63: 207-213.
  11. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. 2000. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 482: 193-199. https://doi.org/10.1016/S0014-5793(00)02042-1
  12. Chandrasekaran S, Marshall JR, Messing JA, Hsu JW, King MR. 2014. TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids. PLoS One 9: e111487. https://doi.org/10.1371/journal.pone.0111487
  13. Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, et al. 2011. Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br. J. Cancer 105: 1830-1838. https://doi.org/10.1038/bjc.2011.456
  14. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. 2013. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32: 1341-1350. https://doi.org/10.1038/onc.2012.164
  15. Stuckey DW, Shah K. 2013. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol. Med. 19: 685-694. https://doi.org/10.1016/j.molmed.2013.08.007
  16. Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. 2015. Targeting TRAIL in the treatment of cancer: new developments. Expert Opin. Ther. Targets 19: 1171-1185. https://doi.org/10.1517/14728222.2015.1049838
  17. Schneider P. 2000. Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol. 322: 325-345.
  18. Cha SS, Shin HC, Choi KY, Oh BH. 1999. Expression, purification and crystallization of recombinant human TRAIL. Acta Crystallogr. D Biol. Crystallogr. 55: 1101-1104. https://doi.org/10.1107/S090744499900164X
  19. Gasparian ME, Ostapchenko VG, Yagolovich AV, Tsygannik IN, Chernyak BV, Dolgikh DA, et al. 2007. Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase. Biotechnol. Lett. 29: 1567-1573. https://doi.org/10.1007/s10529-007-9446-y
  20. Lin Z, Lei H, Cao P. 2007. Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Protein Expr. Purif. 51: 276-282. https://doi.org/10.1016/j.pep.2006.07.026
  21. Wang D, Shi L. 2009. High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Appl. Biochem. Biotechnol. 157: 1-9. https://doi.org/10.1007/s12010-007-8079-x
  22. Singh SM, Panda AK. 2005. Solubilization and refolding of bacterial inclusion body proteins. J. Biosci. Bioeng. 99: 303-310. https://doi.org/10.1263/jbb.99.303
  23. Li P, Gu Q, Wu X. 2016. Fed-batch production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in soluble form in Escherichia coli and its purification and characterization. Protein Expr. Purif. 126: 115-121. https://doi.org/10.1016/j.pep.2016.06.007
  24. Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S, et al. 2000. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J. Biol. Chem. 275: 31171-31177. https://doi.org/10.1074/jbc.M004414200
  25. Vu TT, Koo BK, Song JA, Chong SH, Park CR, Nguyen MT, et al. 2015. Soluble overexpression and purification of bioactive human CCL2 in E. coli by maltose-binding protein. Mol. Biol. Rep. 42: 651-663. https://doi.org/10.1007/s11033-014-3812-3
  26. Nguyen MT, Krupa M, Koo BK, Song JA, Vu TT, Do BH, et al. 2016. Prokaryotic soluble overexpression and purification of human VEGF165 by fusion to a maltose binding protein tag. PLoS One 11: e0156296. https://doi.org/10.1371/journal.pone.0156296
  27. Rosano GL, Ceccarelli EA. 2014. Recombinant protein expression in Escherichia coli: advances and challenges. Front. Microbiol. 5: 172.
  28. Vera A, Gonzalez-Montalban N, Aris A, Villaverde A. 2007. The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol. Bioeng. 96: 1101-1106. https://doi.org/10.1002/bit.21218
  29. Schellman JA. 1997. Temperature, stability, and the hydrophobic interaction. Biophys. J. 73: 2960-2964. https://doi.org/10.1016/S0006-3495(97)78324-3
  30. Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, et al. 2014. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation 130: 35-50. https://doi.org/10.1161/CIRCULATIONAHA.113.007124
  31. Vu TT, Jeong B, Yu J, Koo BK, Jo SH, Robinson RC, et al. 2014. Soluble prokaryotic expression and purification of crotamine using an N-terminal maltose-binding protein tag. Toxicon Official J Int. Soc. Toxinol. 92: 157-165. https://doi.org/10.1016/j.toxicon.2014.10.017
  32. Raran-Kurussi S, Waugh DS. 2012. The ability to enhance the solubility of its fusion partners is an intrinsic property of maltose-binding protein but their folding is either spontaneous or chaperone-mediated. PLoS One 7: e49589. https://doi.org/10.1371/journal.pone.0049589
  33. Liu Y, Zhao TJ, Yan YB, Zhou HM. 2005. Increase of soluble expression in Escherichia coli cytoplasm by a protein disulfide isomerase gene fusion system. Protein Expr. Purif. 44: 155-161. https://doi.org/10.1016/j.pep.2005.03.030
  34. Nguyen MT, Koo BK, Thi Vu TT, Song JA, Chong SH, Jeong B, et al. 2014. Prokaryotic soluble overexpression and purification of bioactive human growth hormone by fusion to thioredoxin, maltose binding protein, and protein disulfide isomerase. PLoS One 9: e89038. https://doi.org/10.1371/journal.pone.0089038
  35. Shen YL, Xia XX, Zhang Y, Liu JW, Wei DZ, Yang SL. 2003. Refolding and purification of Apo2l/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. Biotechnol. Lett. 25: 2097-2101. https://doi.org/10.1023/B:BILE.0000007072.56577.0c
  36. de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L. 2016. Onto better TRAILs for cancer treatment. Cell Death Differ. 23: 733-747. https://doi.org/10.1038/cdd.2015.174
  37. Trabzuni D, Famulski KS, Ahmad M. 2000. Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem. J. 350: 505-510. https://doi.org/10.1042/bj3500505
  38. Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva AM, et al. 2009. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis 14: 778-787. https://doi.org/10.1007/s10495-009-0349-3
  39. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS. 2003. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J. Immunol. 171: 1526-1533. https://doi.org/10.4049/jimmunol.171.3.1526
  40. Qiu F, Hu M, Tang B, Liu X, Zhuang H, Yang J, et al. 2013. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy. Sci. Rep. 3: 3565. https://doi.org/10.1038/srep03565
  41. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC. 2008. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol. Cancer Ther. 7: 851-861. https://doi.org/10.1158/1535-7163.MCT-07-0533
  42. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682. https://doi.org/10.1016/1074-7613(95)90057-8
  43. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, et al. 2004. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J. Biol. Chem. 279: 40044-40052. https://doi.org/10.1074/jbc.M404541200
  44. van der Sloot AM, Mullally MM, Fernandez-Ballester G, Serrano L, Quax WJ. 2004. Stabilization of TRAIL, an all-beta-sheet multimeric protein, using computational redesign. Protein Eng. Des. Sel. 17: 673-680. https://doi.org/10.1093/protein/gzh079
  45. Pan LQ, Zhao WB, Lai J, Ding D, Wei XY, Li YY, et al. 2015. Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities. Sci. Rep. 5: 14872. https://doi.org/10.1038/srep14872

Cited by

  1. Soluble Prokaryotic Overexpression and Purification of Human GM-CSF Using the Protein Disulfide Isomerase b′a′ Domain vol.22, pp.10, 2021, https://doi.org/10.3390/ijms22105267
  2. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion vol.22, pp.12, 2017, https://doi.org/10.3390/ijms22126483